# A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

> **NCT04501770** · PHASE1 · COMPLETED · sponsor: **Wuhan YZY Biopharma Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- HER2-Positive Solid Tumors

## Interventions

- **DRUG:** Chort 1 of M802
- **DRUG:** Chort 2 of M802
- **DRUG:** Cohort 3 of M802
- **DRUG:** Cohort 4 of M802
- **DRUG:** Cohort 5 of M802
- **DRUG:** Cohort 6 of M802
- **DRUG:** Cohort 7 of M802
- **DRUG:** Cohort 8 of M802

## Key facts

- **NCT ID:** NCT04501770
- **Lead sponsor:** Wuhan YZY Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-27
- **Primary completion:** 2022-05-06
- **Final completion:** 2022-09-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501770, "A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04501770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*